BusinessAxsome Therapeutics Reports Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 8, 2017, 12:01 PM UTC
BusinessAxsome Therapeutics Appoints Myrtle Potter to its Board of DirectorsBy Nasdaq OMXJun 19, 2017, 11:00 AM UTC
BusinessAdamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017By Nasdaq OMXMay 2, 2017, 8:08 PM UTC
BusinessAdamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with EpilepsyBy Nasdaq OMXJan 3, 2017, 9:53 PM UTC
BusinessMRI Interventions’ ClearPoint® Neuro-Navigation System to be Featured at the Congress of Neurological Surgeons (“CNS”), in a Hands-On Workshop Entitled, “Laser Ablation Surgery Practical Clinic”By Nasdaq OMXSep 21, 2016, 1:00 PM UTC
BusinessAxsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant DepressionBy Nasdaq OMXMar 17, 2016, 11:00 AM UTC
